OLMA — Olema Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1750284 ·
Last close
$11.45
Market Cap
$1.00B
52W High
$15.64
52W Low
$9.06
ADV30
1,544,143
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -57,986,000 | -53,089,000 | 530,645,000 | 52,547,000 | 50,167,000 |
| Dec 2025 | 0 | — | -50,084,000 | -46,061,000 | 533,430,000 | 48,301,000 | 54,871,000 |
| Sep 2025 | 0 | — | -45,877,000 | -42,217,000 | 352,453,000 | 35,260,000 | 44,965,000 |
| Jun 2025 | 0 | — | -47,864,000 | -43,784,000 | 382,002,000 | 52,473,000 | 36,766,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-148,724,000
Investing CF
$-106,148,000
Financing CF
$256,779,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.88
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-650,646,000
Inventory
—
Receivables
$3,351,000
ST Investments
$452,800,000
EBIT TTM
$-201,811,000
Pretax Income TTM
$-185,151,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -178,698,000 | -162,451,000 | 533,430,000 | 54,871,000 | — | -146,716,000 |
| Dec 2024 | 0 | -142,258,000 | -129,474,000 | 450,979,000 | 42,015,000 | — | -104,351,000 |
| Dec 2023 | 0 | -104,961,000 | -96,655,000 | 276,945,000 | 23,050,000 | — | -83,727,000 |
| Dec 2022 | 0 | -106,988,000 | -104,787,000 | 215,645,000 | 18,099,000 | — | -82,065,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | $992.53M | $15.14 | — |
| OPK | OPKO HEALTH, INC. | $985.15M | $1.32 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.03B | $2.31 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $969.12M | $6.57 | — |
| AVTX | Avalo Therapeutics, Inc. | $965.48M | $18.25 | — |
News headlines (Yahoo Finance, 1h cache)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:30 · Yahoo
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
2026-06-30 12:07 · Yahoo
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
2026-06-17 15:17 · Yahoo
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
2026-05-26 11:00 · Yahoo
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap
2026-05-25 19:05 · Yahoo
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study
2026-05-22 13:06 · Yahoo
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
2026-05-20 17:00 · Yahoo
Olema Oncology to Participate in Upcoming Investor Conferences
2026-05-19 20:30 · Yahoo
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
2026-05-15 21:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.